Adult Dosing
Treatment of erosive/ulcerative GERD
- 20 mg PO daily x 4-16 wks
- Info: Do not cut/crush/chew
Maintenance in GERD
- 20 mg PO daily
- Info: Do not cut/crush/chew
Treatment of symptomatic non-erosive GERD
- 20 mg PO daily x 4-8 wks
- Info: Do not cut/crush/chew
Duodenal ulcer
- 20 mg PO daily after morning meal x 4 wks
- An additional 4 wks treatment may be considered for patients who do not heal
- Info: Do not cut/crush/chew
Hypersecretory conditions
- 60 mg PO daily; Max: 120 mg PO daily
- Doses up to 100 mg PO qd and 60 mg PO bid; should be adjusted according to response and continue for as long as clinically indicated
- Info: Do not cut/crush/chew
- Patients with Zollinger-Ellison syndrome have been treated continuously with up to one year
Helicobacter pylori eradication
- 20 mg PO bid for 7 days in helicobacter pylori eradication regimen
- Info: Do not cut/crush/chew
Pediatric Dosing
Treatment of erosive/ulcerative GERD
- Child >12 yrs: 20 mg PO daily for 4-8 wks
- Info: Do not cut/crush/chew
Treatment of GERD (sprinkle)
- Child 1-11 yrs (<15 kg): 5 mg PO daily for 12 wks, may increase the dose to 10 mg/day if inadequate response
- Child 1-11 yrs (
15 kg): 10 mg PO daily for 12 wks
Note:
- Delayed Release CAPS should be sprinkled on a spoonful of soft food or liquid and the whole dose should be taken within 15 minutes of being sprinkled
[Outline]
See Supplemental Patient Information
- Patients treated with a proton pump inhibitor and warfarin may need to be monitored for increases in INR and prothrombin time due to risk of abnormal bleeding
- Angioedema and anaphylactic reaction/shock have been reported in patients taking esomeprazole
- Long-term therapy with proton pump inhibitors may cause atrophic gastritis. This may also occur with rabeprazole
- Relief of symptoms does not preclude the presence of a gastric malignancy. Evaluate for gastric malignancy prior to starting treatment
- Use of proton pump inhibitors may increase risk of gastrointestinal infection
- Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine
- Use of PPIs with high dose methotrexate may increase and prolong serum levels of methotrexate and its metabolite leading to methotrexate toxicities. Temporary withdrawal of the PPI must be consider in patients who are on high-dose of methotrexate
- PPI therapy including rabeprazole may increase risk of Clostridium difficile associated diarrhea, particularly in hospitalized patients
Cautions: Use cautiously in
- Severe hepatic impairment
- Lactation
- Penicillin-sensitive patients
- Hypersensitivity
- Long-term use
- High dose therapy
- Patients >50 yrs (high dose or long-term use)
- Hypomagnesemia
Supplemental Patient Information
- Tablets should be swallowed whole. The tablets should not be chewed, crushed, or split. Can be taken with or without food
Pregnancy Category:B
Breastfeeding: Safety unknown; an alternate drug may be preferred, especially while nursing a newborn or preterm infant. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 25 April 2011). Due to the potential for serious adverse reactions in nursing infants, manufacturer recommends discontinuation of nursing or discontinuation of drug, taking into account the importance of the drug to the mother.
Pricing data from www.DrugStore.com in U.S.A.
- Aciphex 20 MG TBEC [Bottle] (EISAI)
30 mg = $249.99
90 mg = $707.98
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
Drug Name: Aciphex 20 MG Enteric Coated Tablet
Pill Image:
[
See full size image]
Ingredient(s): Rabeprazole
Imprint: ACIPHEX;20
Color(s): Yellow
Shape: Round
Size (mm): 8.00
Score: 1
Inactive Ingredient(s): carnauba wax / crospovidone / diacetylated monoglycerides / ethylcellulose / hydroxypropyl cellulose / hypromellose phthalate / magnesium stearate / mannitol / sodium hydroxide / sodium stearyl fumarate / talc / titanium dioxide / yellow ferric oxide
Drug Label Author:
Eisai Inc.
DEA Schedule:
Non-Scheduled
